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Background: The HIV-1 matrix protein (MA) binds
both RNA and phospholipids.
Results: Ligands that compete with RNA for
binding to MA were identified and characterized.
Conclusion: Thiadiazolanes bind to residues in the
HIV-1 MA β-II-V cleft that mediates RNA and
phospholipid binding to MA.
Significance: These investigations provide new
insights as to MA-ligand binding and antiviral
design.
SUMMARY
The matrix (MA) domain of the HIV-1
PrGag protein directs PrGag proteins to
assembly sites at the plasma membrane by virtue
of its affinity to the phospholipid,
phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2).
MA also binds to RNA at a site that overlaps its
PI(4,5)P2 site, suggesting that RNA binding  may
protect MA from associating with inappropriate
cellular membranes prior to PrGag delivery to
the PM. Based on this, we have developed an
assay in which small molecule competitors to
MA-RNA binding can be characterized, with the
assumption that such compounds might interfere
with essential MA functions and help elucidate
additional features of MA binding. Following this
approach, we have identified four compounds,
including three thiadiazolanes, that compete with
RNA for MA binding. We also have identified
MA residues involved in thiadiazolane binding
and found that they overlap the MA PI(4,5)P2
and RNA sites. Cell culture studies demonstrated
that thiadiazolanes inhibit HIV-1 replication, but
are associated with significant levels of toxicity.
Nevertheless, these observations provide new
insights as to MA binding, and pave the way for
the development of antivirals that target the HIV-
1 matrix domain.
INTRODUCTION
While current anti-HIV therapies target
products of the pol gene, the development of drugs
that target the HIV-1 Gag proteins, which direct
virus assembly is of biomedical interest1-6. The HIV-
1 matrix domain (MA) is the N-terminal cleavage
product of the HIV-1 precursor Gag (PrGag) protein.
 http://www.jbc.org/cgi/doi/10.1074/jbc.M112.399865The latest version is at 
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2Initially, PrGag is synthesized on cytosolic
ribosomes and becomes cotranslationally
modified by the N-terminal attachment of a
myristoyl group by N-myristoyl-transferase
7-9. Myristoylated Gag precursors associate
with the inner layer of the plasma membrane
(PM), where they oligomerize, assemble,
and bud off from cells as immature virions.
During the maturation process, cleavage of
PrGag by the viral protease (PR) generates
the mature MA protein as well as capsid
(CA), nucleocapsid (NC), p6 and two spacer
peptides 5, 6. The MA domain plays multiple
roles in the viral replication cycle. One
essential role of MA is the incorporation of
the viral surface/transmembrane (SU/TM)
envelope (Env) protein complex into virions
10-16. Another essential function is to target
PrGag proteins to their lipid raft-associated
phosphatidylinositol-(4,5)-bisphosphate
(PI[4,5]P2) assembly sites at the PMs of
infected cells 17-25. Furthermore, MA
oligomerization at membrane lipid rafts
appears to trigger a myristate switch, in
which the buried myristate group becomes
exposed, and inserts into lipid bilayers,
therefore promoting membrane binding 18, 23,
26-28.  In addition to membrane and Env
protein binding, several reports have
ascribed nucleic acid binding properties to
retroviral MAs 29-35, and it is possible that
such binding might facilitate PrGag delivery
to the PM, virus assembly, and/ or nuclear
import of viral preintegration complexes
(PICs) 36-42.
How does the structure 27, 28, 32, 43-45 of
MA accommodate all these essential
functions? In addition to its N terminal
myristate, which is essential for membrane
binding 8, 25, 46, 47, MA is composed of
globular domain consisting of 5 helices and
three β sheet strands 27, 28, 43-45. The
membrane-binding face of HIV-1 MA is
composed of a basic patch, promoting
interactions with negatively charged
phospholipid headgroups at the inner leaflets
of PMs 27, 28, 43-45, and this patch selectively
binds PI(4,5)P2 32-34, 45, 48, 49. It has been
shown that depletion of PM PI(4,5)P2 by
overexpression of polyphosphoinositide 5-
phosphatase IV reduced HIV-1 assembly
efficiency, resulting in the delivery of viral
proteins to intracellular compartments 49, 50.
NMR investigations have indicated that
HIV-1 MA preferentially binds to soluble
PI(4,5)P2 mimics through contacts with the
lipid headgroup and its 2' acyl chain, and
that binding promotes both exposure of the
MA myristate group and protein
oligomerization 28, 45. Consistent with the
above observations, we have shown that MA
proteins tend to organize as hexamers of
trimers on lipid membranes containing
PI(4,5)P2 51, and that the binding specificity
of MA is enhanced by cholesterol 32-33.
In addition to the MA membrane-binding to
acidic lipids, several lines of experimentation have
shown that HIV MA has a nucleic acid binding
capacity that includes the highly basic region of MA
29-32, 34, 41, 42, 52-54. Moreover, we have shown that
RNA binding enhances the binding specificity of
MA to PI(4,5)P2-containing membranes. This was
evident by the fact that PI(4,5)P2-containing
liposomes successfully competed with nucleic acids
for MA binding, whereas other liposomes did not 32,
33. In agreement with our results, RNAse treatment
of Gag synthesized in vitro using rabbit reticulocyte
lysate significantly reduced the selectivity of Gag
binding to PI(4,5)P2 liposomes as opposed to PS-
containing liposomes 34. We recently analyzed HIV
MA interactions with RNA ligands that previously
were selected for their high affinities to MA 30, and
we identified MA residues that are involved in RNA
binding evident by NMR chemical shift data 33:
interestingly, the RNA and PI(4,5)P2 binding sites
overlap. These and results from other labs 34, 55
suggest that RNA may provide a chaperone function
in preventing Gag proteins from binding to
membranes until they reach PI(4,5)P2-rich plasma
membranes.
To further characterize the binding
properties of HIV-1 MA, we have identified and
analyzed inhibitors of MA-RNA interactions.
Specifically, using a competition assay for RNA
binding to MA, we have identified a group of
compounds that inhibit the MA-RNA binding
activity. Interestingly, several such compounds are
thiadiazolanes. We characterized these ligands with
respect to their MA binding via nuclear magnetic
3resonance spectroscopy (NMR), fluorescence
anisotropy (FA), bead binding assays, and
electrophoretic mobility shift assays (EMSA). Our
studies demonstrate that MA-thiadiazolane binding
sites overlap the MA-RNA and MA-PI(4,5)P2
binding sites and identify residues in the β-II-V cleft
and the C-terminus of helix II as binding elements.
Moreover, thiadiazolanes were shown to inhibit
HIV-1 replication in cell culture, but also
demonstrated cytotoxicity. Despite this, our efforts
provide new insights as to the nature of MA-RNA
and MA-PI(4,5)P2 binding sites, and open the door
to the development of new classes of HIV antivirals.
EXPERIMENTAL PROCEDURES
Protein preparation. The myristoylated
HIV-1 MA protein (MyrMA), as well as the
unmyristoylated MA protein (MA), were
expressed in Escherichia coli strain
BL21(DE3)/pLysS (Novagen) along with
Saccharomyces cerevisiae N-
myristyltransferase from pET-11a-based
vectors kindly provided by Michael F.
Summers (University of Maryland
Baltimore County) as described previously
27, 28, 32, 33, 45, 63. The MA protein was prepared
similarly to MyrMA, except that myristic
acid was excluded from the bacterial growth
media during the induction phase. The
proteins were desalted by three rounds of
buffer exchange using dialysis buffer of 10
mM sodium phosphate (pH 7.8) and 50 mM
NaCl, supplemented with β-mercaptoethanol
(BME; 1 mM final concentration),
aliquoted, and stored at -80°C under
nitrogen gas. 15N isotopically labeled
proteins were prepared by growing cells on
15NH4Cl (Cambridge Isotopes; NLM-467-5)
as the sole nitrogen source as described
previously 27, 28, 33, 43, 45, 63. For NMR studies,
the proteins were dialyzed against 50 mM
sodium phosphate (pH 5.5), 100 mM NaCl
and 5 mM dithiothreitol (DTT), and then
concentrated by Millipore ultrafiltration
concentrators against the same buffer.
Protein purities were evaluated after
fractionation by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-
PAGE; 32, 33, 64-68 by Coomassie blue staining
32, 64-66. The HIV nucleocapsid (NC) peptide
was prepared commercially as reported
previously 68.
RNA Samples. The RNA oligomers used
for our studies were selected for high
affinity binding to MA 30, 33. The consensus
sequence for the high affinity RNA ligand to
HIV-1 MA derived from screening of
random 76 mer and 31 mer libraries as
described previously 30, 31, yielding a
consensus, 5’GGAAU UAAUA GUAGC3’
(Sel15). We also prepared a 25mer stem-
loop (Sel25) version of Sel15 that retained
its high MA binding affinity: its sequence is
5’ GGACA GGAAU UAAUA GUAGC
UGUCC3’. As controls, we prepared a
randomized version (Ran25) of Sel25, with
the sequence of 5’GGACA GAAGG
AGAUU UAUAC UGUCC3’ and a
randomized version of Sel15 with the
sequence 5’GAAGG AGAUU UAUAC3’.
In addition to the untagged RNAs, for plate
binding studies, we procured biotinylated
Sel15 and Sel25 RNAs from Invitrogen. We
also procured fluorescently 5’ tagged
versions of Sel15, Ran15, Sel25, and Ran25
from Invitrogen. Another fluorescently
labeled RNA corresponded to HIV-1 Mal
isolate viral RNA (vRNA) nucleotides (nt)
1-4001. This was prepared by T7 RNA
polymerase transcription from a SalI-
linearized SP64HIV1-4005 plasmid (kindly
provided by J.-C. Paillart, CNRS-Université
de Strasbourg) as described previously32 but
with the use of 0.5 mM unlabeled nucleoside
triphosphates plus 0.1 mM Cy3-CTP (GE
Healthcare) in the transcription buffers.
Plate binding studies. Assay plates were 96
well nickel-NTA coated plates, purchased
from Pierce and stored at 4 C°. Plate wells
were coated with 2 µg of C-terminally his-
tagged MyrMA in 100 ml sodium phosphate
buffer (25mM NaPhos pH 7.8, 10mM NaCl)
by 16 h 4°C binding incubations. Following
this step, unbound proteins were removed
from wells and wells were washed twice
with 200 µl of incubation buffer (0.1 mg/ml
bovine serum albumin [BSA], 25mM
NaPhos pH 7.8, 10mM NaCl) using a plate
washer (Multiwash III; Tricontinent). After
4these washing steps, 250 nM biotinylated-
Sel15 RNA was added in the presence of
appropriate RNA-binding inhibition controls
(dimethyl sulfoxide [DMSO], unlabeled
RNA) or with compounds [in DMSO] to be
tested in a final volume of 100 µl. Our
compound library (Maybridge Hitfinder
;14,000 compounds) was available in 96-
well plates and each compound was
dissolved in DMSO to a concentration of 1
mM, with stock plates stored at  -20°C. All
controls (including 1 µl DMSO, 1.2 µM
unlabeled Sel25 and Ran25, and no-protein
mocks) were tested in every plate. The
remaining columns were treated with 10 µM
final concentrations of library compounds (1
µl of 1 mM). After 30 min incubations,
unbound solutions were removed and plates
were washed twice with 200 µl of
incubation buffer per well.  After the
binding and washing steps, 4 µg/ml alkaline
phosphatase-conjugated streptavidin
(Invitrogen) in Dulbecco’s Modified Eagles
Media (DMEM) plus 10% calf sera was
added and incubated for 45 min at 4° C.
This was followed by removal of alkaline
phosphatase and 5 washes of each well with
200 µl incubation buffer. The bound
biotinylated-Sel15 RNA levels were
detected by alkaline phosphatase reactions
with 3 mg/ml substrate p-nitrophenyl
phosphate (pNPhP; Sigma) in 1X assay salt
(95 mM diethanolamine pH 9.85, 280 mM
NaCl, 0.5 mM MgCl2). Absorbance was
monitored at 420 nm (Molecular Device
plate reader) for 10-60 min, and
experimental samples were compared with
controls from plates in which average
positive control absorbance readings were
1.0. The effective inhibition by a given
molecule from the library was calculated
with respect to positive controls and
absorbances normalized relative to DMSO
controls were graphed.  The hit threshold
was set at ≤ 0.6 and qualifying compounds
were retested in the secondary screen. Note
that negative control values of samples
supplemented with 1.2 µM Sel15 competitor
were ten-fold lower than positive controls;
that the Z screening window coefficient for
positive and negative controls was 0.69; and
that 1 mM guanidinium chloride, 1 mM
EDTA, and 1% DMSO did not interfere
with MA-RNA binding.
Fluorescence Polarization. Fluorescence
polarization (fluorescence anisotropy [FA])
assays were used to measure inhibitor
interference with MA-RNA binding.
Measurements were conducted as described
previously 33. Measurements were obtained
using a Pan Vera Beacon 2000 fluorescence
polarizer (Invitrogen) with a 490 nm
excitation wavelength. All readings were
obtained at room temperature. For
competition binding assays, samples of one
ml of 5 nM FITC-labeled Sel15 RNA in pH
7.8 buffer (25 mM sodium phosphate [pH
7.8], 50 mM NaCl) plus or minus 1 µM
MyrMA, were in 12 x 75 mm disposable
borosilicate glass tubes. For competition,
increasing concentrations of compounds or
DMSO (as a control) were titrated from 0 to
60 µM. Polarization values correspond to
emitted light intensities as defined by the
ratio (parallel – perpendicular)/ (parallel +
perpendicular); 69). Competition assays were
fitted assuming exponential decay binding
curves using Prism (www.graphpad.com).
Competition electrophoretic mobility shift
assays. RNA and MA samples were
prepared in stocks containing 25 mM
sodium phosphate (pH 7.8), 50 mM NaCl.
For 20 µl binding reactions, 15 µM RNA
was mixed with 15 µM MA in the presence
of either 1 µl DMSO or 1 µl of 1 mM stock
compounds in DMSO (50 µM final
concentration).  Samples were incubated at
35 °C for 30 min. Following incubations,
samples were supplemented with 6 µl of
50% glycerol, and then loaded onto 12%
native polyacrylamide (37.5:1 acrylamide:
bis; polymerized with 0.0375% ammonium
persulfate and 0.1125% TEMED) gels in 0.5
x Tris-borate buffer (44.5 mM Tris base,
44.5 mM boric acid, pH 8.0) 33, 70. Gels were
electrophoresed at 4 °C at 30–35 mA. For
visualization of bound and free RNAs, gels
were stained with Stains-all (Sigma),
5destained by light exposure, and scanned
immediately on an Epson Perfection 1240U
scanner. Band intensities were obtained with
Image J 32, 33, 66 software.
Bead binding assays. Bead binding assays
followed our previously established
protocols32-33. For the assays, 0.2 ml aliquots
of packed nickel-nitrilotriacetic acid
(Qiagen) beads were washed with 0.5 ml of
wash buffer (25 mM sodium phosphate [pH
7.8], 50 mM NaCl, 0.1 mg/ml bovine serum
albumin [Sigma A4503]), suspended in 0.5
ml of wash buffer supplemented with 20 µl
of 10-mg/ml bovine serum albumin,
incubated for 5 min at 4°C, and washed
three times with 0.3 ml wash buffer. After
the washes, packed beads were
supplemented with 0.2 ml wash buffer plus
2-3 µg of his-tagged MyrMA. Proteins and
beads were incubated for 2 h at 4°C, after
which beads were pelleted, washed twice
with 0.3 ml wash buffer, and suspended in a
total volume of 360 µl wash buffer on ice:
the estimated bead-bound MA concentration
used in each assay was 300 nM.
For RNA competition binding
assays, two fluorescently tagged RNAs were
used. One was FITC-Sel25 (Invitrogen) and
the second RNA corresponded to viral HIV-
1 Mal isolate RNA nucleotides (nt) 1 to
4001, prepared as described in the RNA
Samples section above. To perform
competition assays, MyrMA-coated beads in
60 µl wash buffer were supplemented first
with either 1 µl DMSO or 1 µl of stock
compounds in DMSO (50 µM final
concentration). Samples were incubated for
1 hour at 4°C. Following incubations,
samples were supplemented with either
FITC-Sel25 RNA (0.5 µM; 13 µM total
nucleotide concentration) or HIV-1 viral
RNA (nt 1-4001; 23 µM total nucleotide
concentration), and incubated for 1 h at 4°C,
after which beads were pelleted (1 min;
13,700 x g), quickly washed twice with 300
µl wash buffer, and resuspended in 60 µl of
wash buffer on ice.
Liposome competition assays
employed liposomes prepared as described
previously32 from stock solutions in
chloroform of cholesterol (Sigma), 1,2-
dioleoyl-sn-glycerol-3-phosphocholine (PC;
Avanti), 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(7-nitro-2-
1,3benzoxadiazol-4-yl) (NBD-DOPE;
Avanti), and brain phosphatidylinositol-
(4,5)-bisphosphate [PI(4,5)P2 (Avanti)].
Lipids were dried in glass vials with a
stream of nitrogen gas, supplemented with
liposome buffer (10 mM HEPES [pH 7.4],
50 mM NaCl, 0.002% sodium azide), and
suspended by twenty 30 second rounds of
sonication in a Branson 1210 bath sonicator,
with incubations on ice between each
sonication round. Final liposome lipid
concentrations were 2 mg/ml, and liposomes
were stored for up to 1 week under nitrogen
at –20°C. By weight, brain PI(4,5)P2
liposomes were prepared at 10% (wt/wt) and
contained 20% cholesterol, 69.8% PC, and
0.2% NBD-DOPE. For liposome
competition assays, MyrMA-coated beads
were prepared and preincubated with DMSO
or compounds in DMSO as described above.
Samples so prepared were supplemented
with 4 µg of liposomes, and incubated for
16-18 h at 4°C, after which beads were
pelleted (1 min; 13,700 x g), quickly washed
twice with 300 µl wash buffer, and
resuspended in 50 µl of wash buffer on ice.
For viewing of fluorescent RNA or
liposome ligands on MyrMA beads, samples
were mixed by pipetting up and down and
10 µl samples were applied to microscope
slides and covered with  22 mm by 22 mm
coverslips. Fluorescent green beads were
imaged on a Zeiss AxioPlan fluorescence
microscope using a 20x (LDA-Plan)
objective and Zeiss filter set 10 (excitation
band-pass, 450 to 490; beam splitter Fourier
transform, 510; emission band-pass, 515 to
565). For every individual experiment,
exposure and gain settings were identical,
and care was taken to make sure that
brightness values (on a scale of 0 to 4,095)
were below the maximum. After collection
6of multiple bead images per sample as gray-
scale tagged-image-file-format (TIFF) files
using Improvision OpenLab software,
images were ported to NIH Image J for
analysis, as described previously32−33. For
each bead, normalized bead brightness
values were determined. To do so, areas and
average brightness values were collected
from circled beads. Average background
brightness values were calculated by
dividing total image average brightness
values (with bead area brightness values
zeroed out) by total image areas minus bead
areas. Normalized bead brightness values
(average bead brightness minus background
brightness) were averaged for all beads of a
given incubation in an experiment, and
results of experiments were normalized to
results with DMSO containing samples.
Tissue culture toxicity and efficacy assays.
To test the compound toxicities, cells were
treated with increasing compound
concentrations and assayed for
dehydrogenase levels using MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) substrate 62. The assay
measures the formation of a soluble
formazan product that is proportional to the
number of live cells in culture. Briefly,
293M cells (adherence adapted HEK 293T
cells; 71, 72 ) were plated at 15,000 cells per
96-well plate well in DMEM plus 10% fetal
bovine serum (FBS) and incubated for 24
hours at 37°C/ 5% CO2. The supernatants
were then removed, and cells were refed
with 150 µl of DMEM plus 2% FBS, along
with 1.5 µl DMSO or test compounds in 1.5
ml. The plates were incubated for 48 h, after
which 30 µl of MTS reagent was added to
each well. Plates then were incubated 60–90
min and read on a 96-well plate reader at
490 nm.
To test the effects on infectivity, a
TZM-bl assay was employed. This assay
employed CCR5+, CD4+ TZM-bl cells that
express a β-galactosidase (β-gal) reporter
when infected by HIV-1 60, 61. Briefly,
human CEM-SS T cells cultured in RPMI
plus 10% FBS were infected with HIV wild-
type (wt) NL4-3 virus and left to incubate
for 4 days. On the fourth day, infected
CEM-SS cells were pelleted, washed three
times with 10 ml RPMI, and re-suspended in
5 mL RPMI. Cells were counted and plated
at 10,000 cells and 100 ml per well in RPMI
plus 10% FBS per well on 96-well plates,
treated with 1 µl of DMSO or compound in
DMSO and incubated for 48 h. After 48 h,
wells were supplemented with 75,000 TZM-
bl cells (in 100 µl RPMI + 10 % FBS),
treated with another 1 µl of DMSO or
compound in DMSO and incubated for
another 48 h. Following this incubation,
supernatants were removed from the wells,
and the adherent TZM-bl cells were lysed
with 40 µl phosphate buffer saline (PBS)
containing 0.1% sodium dodecyl sulfate
(SDS). Following 5 min, wells of lysates
were supplemented with 200 µl of 1X PM-2
(2mM MgSO4, 0.1mM MnCl2, 33mM
NaH2PO4, 66mM Na2HPO4), containing
40 mM ß-Mercaptoethanol (BME) and 0.89
mg/ml ortho-nitrophenyl-ß-galactoside
(ONPG). After 10-30 min incubations, the
plates were read for absorbance at 420 nm.
Signals for both TZM-bl and MTS assays
were plotted as normalized values of DMSO
controls.
NMR Spectroscopy. NMR data were
collected at 35 °C on a Bruker Avance III
(600 MHz 1H) spectrometer, processed with
Bruker-Topspin 2.1 software (BRUKER,
http://www.bruker-biospin.com), and
analyzed with NMRVIEW 73. All of the
NMR samples were prepared in a buffer
containing 50 mM sodium phosphate at pH
5.5, 100 mM NaCl and 5 mM DTT using
15N uniformly labeled protein samples of 80
µM (10% 2H2O). Amide [1HN–15N]
backbone cross-peaks for MA were
observed using standard two dimensional
(2D) heteronuclear sequential quantum
correlation 2D [1H–15N] HSQC with pulse
program hsqceftf3gp as described
previously74. The 2D HSQC spectra were
recorded as 2048 t2 x 256 t1 data points
with 90° pulses for 1H and 15N of 10 µs and
736 µs respectively. These spectra were
processed by Fourier transformation after
zero-filling to 2048 x 1024 real data points,
followed by phase and baseline correction.
The 2D HSQC spectrum was recorded first
with MA only. Signal assignments and
verification of MA were matched with the
chemical shift assignments that have been
deposited at the BioMagResBank 27, 43. The
association of compounds and MA was
monitored by observing the changes in the
amide 1HN–15N cross-peaks in the HSQC
spectra of 15N labeled MA upon titration
from 50 mM compound stock in DMSO as
described previously 75.  Residues that
exhibited significant chemical-shift changes
upon titration with compounds or DMSO
only were analyzed for the extent of the
combined 1H  and 15N  (ΔδHN) chemical-
shift changes by calculating ΔδHN = ([Δδ
1H]2 + [Δδ 15N]2)-1/2 27, 45. Binding isotherms
from 1H–15N NMR HSQC titration
experiments were calculated using Prism
software (www.graphpad.com). Surface
representations of the MA structure (pdb ID:
1UPH) were generated with PYMOL
(http://pymol.sourceforge.net).
RESULTS
Identification of inhibitors of HIV-1 MA-
RNA binding
Studies have shown that HIV MA possesses
a nucleic acid binding activity that involves the
highly basic region of MA 29-32, 34, 54. Recently, we
reported that RNA binding to MA acts as a
chaperone which protects MA from associating with
inappropriate cellular membranes prior to PrGag
delivery to plasma membrane (PM) assembly sites
33. Previously, in vitro selection experiments
identified a 25mer aptamer Sel25 (GGACA
GGAAU UAAUA GUAGC UGUCC) that showed
high affinity binding to HIV-1 MA 30, 33.  The central
fifteen nucleotides of Sel25, designated Sel15, also
showed high affinity binding to the protein.
Recently, we have characterized binding interactions
of Sel15 RNA to MA, demonstrating that the MA
RNA and PI(4,5)P2 binding sites overlap 33.
To extend our previous observations, we
developed an in vitro MA-RNA binding assay to
identify potential inhibitors of MA-RNA
interactions. Our assay involved binding C-
terminally his-tagged MyrMA to 96 well nickel-
NTA plates, incubation of the plates with biotin-
Sel15 in the presence or absence of potential
competitors, and colorimetric determination of
bound biotin-Sel15 (see Experimental Procedures).
Using the MA-RNA binding assay, we screened a
library of 14,000 compounds for inhibition of
MyrMA-Sel15 RNA binding, looking for candidates
that significantly reduced Sel15 RNA binding to
MyrMA. The robustness of the assay was indicated
by the consistent large difference between samples
containing no inhibitor and those using untagged
Sel15 RNA as an inhibitor control. Moreover, we
obtained a Z screening window coefficient for the
primary screen of 0.6956. Because Z  coefficients
measure assay reliability, and ordinarily can vary
from negative values to an optimum value of 1.056,
our assay conditions appeared well-suited to
inhibitor identification.
From the primary screen, 127 compounds
that gave relative binding values of 0.6 or less were
rescreened. Of these, 11 compounds gave primary
screen values of 0.25 or less. Upon rescreening, five
compounds consistently rescreened as binding
inhibitors and four of these had given primary screen
values of ≤ 0.25. Due to the unavailability of one of
these compounds, four compounds (TD1, TD2,
TD3, and DDD; Figure 1, Table 1) were obtained for
further analysis. Interestingly, three of the four
compounds  (TD1, TD2 and TD3) are
thiadiazolanes, and two other thiadiazolanes (TD4,
TD5) were assayed in our primary screen. However,
at 10 µM concentrations, TD4 and TD5 showed only
modest inhibition of MA-RNA binding levels (Table
1). We also tested two glitazones (Figure 1),
pioglitazone and rosiglitazone, that have a similar
ring structure to thiadiazolanes, and which have been
used to treat diabetes 57, 58. When these compounds
were tested at 10 µM concentrations, they failed to
inhibit MA-RNA binding (Table 1). In contrast,
primary and secondary screen values for TD1-3 and
DDD (Table 1) earmarked them as potential binding
inhibitors.
Characterization of MA-RNA binding inhibitors
8To examine the specificities of
compounds on MA-RNA binding, we
employed native electrophoretic mobility
shift assays (EMSA), using a native
polyacrylamide gel electrophoresis (PAGE)
system. As illustrated in Figure 2, 15 µM
Sel25 or Sel15 RNAs and HIV-1 MyrMA
(MA) or NC proteins were subjected to
EMSAs. Binding of MA to Sel15 or Sel25
RNA resulted in RNA shift bands in the
control sample and in the presence of
DMSO, indicative of the formation of RNA-
protein complexes (top two panels).
However, RNA-Sel15 complex formation
was diminished in the presence of 50 µM
DDD (middle panel), while the same
concentrations of compounds TD1-3
abolished MA binding to either RNA ligand.
In contrast, when NC protein was incubated
with Sel15 RNA and treated with either
DMSO or the indicated compounds shown
in Figure 2, shift bands (bottom panel;
Figure 2) were not affected by compound
treatment. These results demonstrate that
DDD and TD1-3 specifically targeted MA-
RNA interactions, but not RNA-NC binding.
In addition, EMSA results imply that DDD
and TD1-3 did not inhibit MA-plate binding
via targeting his-tag interactions with Ni-
NTA coated plates in the original assay
system.  In agreement with the EMSA
results, and to rule out compound effects on
MA-plate binding, MA-coated plates were
treated with compounds, washed and tested
for reactivity to anti-MA antibodies. No
reductions of MA signals were observed
(data not shown), supporting the notion that
these compounds exert their inhibitory
effects on MA-RNA complex formation.
To confirm the above results, we performed
fluorescence anisotropy (FA) competition binding
assays, where RNA ligands were fluorescently
tagged, and the assay readout was via FA (Figure 3).
Briefly, fluorescently tagged Sel15 RNA was
incubated in the presence or absence of purified MA,
and challenged with increasing concentrations of
compounds. As illustrated in panel A, in the absence
of MA, increasing concentrations of DMSO or
compounds in DMSO led to diminutions of FA
signals, probably due to fluorescence quenching 59.
However, in the presence of MA (panel B), results
were different. Relative to DMSO, DDD did not
have a significant effect on FA signals. In contrast,
TD1-3 reduced RNA-MA binding levels. These
results parallel our EMSA results (Figure 2), and
demonstrate that the thiadiazolanes TD1-3 compete
with Sel15 RNA for MA binding.
As another approach to assess compound
effects on MyrMA-Sel RNA binding, we employed
bead binding assays, as we have previously32. To do
so, MyrMA-bound beads were incubated with
fluorescently tagged Sel25 RNA in the presence of
DMSO, TD1-3, or DDD. After incubations, Sel25
RNA binding levels were quantified and normalized
to levels obtained in DMSO control incubations.
Results from these assays (Figure 4A) were
consistent  with both EMSA (Figure 2) and FA
(Figure 3) analyses, in that TD1-3 clearly reduced
MyrMA-Sel RNA binding signals, whereas DDD
did not. Because the bead binding protocol is
compatible with the analysis of MA binding to
longer RNAs, we also performed experiments with a
fluorescently tagged 4001 nt RNA representing the
5' part of the HIV-1 genomic viral RNA. Results
(Figure 4B) showed that DDD failed to inhibit HIV
RNA binding to MyrMA. The thiodiazolanes had
less profound effects on HIV RNA binding than on
Sel25 RNA binding, possibly due to the capacity of
the 4001 nt RNA to bind to a larger number of
MyrMA monomers than the Sel25 RNA.
Nevertheless, TD1-3 clearly gave reductions of HIV
RNA-MA binding, consistent with a competition for
the MA-RNA binding site. The bead binding assay
also allowed us to examine the potential influence of
compounds on the MA-PI(4,5)P2 binding site, which
overlaps the RNA binding site33. For this, MyrMA
beads were incubated with DMSO or compounds,
and then challenged with fluorescently tagged
PI(4,5)P2-containing liposomes, as we have
previously32-33. Figure 4C demonstrates that DDD,
TD3, TD2, and TD1 yielded increasing degrees of
liposome binding inhibition. These observations
support a model in which TDs occude overlapping
MA RNA and PI(4,5)P2 binding pockets.
Identification of binding site residues
To identify thiadiazolane (TD)
binding site residues, NMR chemical shift
perturbation experiments were performed.
9For this assay, we tested TD1 (Figure 1)
along with a DMSO control. The
interactions between MA and TD1 were
monitored by tracking chemical shifts in 2D
HSQC spectra during titrations with TD1.
This approach allows the identification of
MA residues involved in ligand binding 28, 33,
45, and takes advantage of the fact that the
MA NMR structure and databases for 1H,
and 15N assignments were available 27, 43 to
provide a baseline for our comparisons. For
solubility reasons, we performed NMR
HSQC experiments on unmyristoylated MA
as previously done 33. Initially, 2D 1H-15N
HSQC spectra were collected for uniformly
labeled MA, and assignments were cross-
checked with the available assignments of
MA: most of the anticipated cross-peaks
were accounted for and matched the
reported positions for MA (27, 28, 43, 45; Table
2). As illustrated in Figure 5A, high quality
2D HSQC spectra were obtained for MA
upon titration with TD1. While the majority
of signals were not sensitive to TD1
addition, titration of TD1 led to significant
changes in the amide 1H and 15N chemical
shifts of a subset of residues (Figure 5A-E,
Table 2). In particular, we observed
significant shifts (≥ 0.10 ppm) for residues
Ser-6, Trp-16, Leu-21, Lys-32, Val-35, Glu-
40, Leu-41, Arg-43, Val-46, Asn-47, Ile-60,
Glu-73, Leu-75, Ser-77, Leu-78 (Table 2).
Examples of data for Ala-100, which was
unaffected by TD-1 binding, and for
affected residues Leu-21, Lys-32 and Ser-77
are shown in Figures 5B-I. Interestingly,
several shifted residues locate to the matrix
protein β-II-V cleft, and some (residues Ser-
6, Trp-16, Leu-21, Lys-73, Leu-75 and Ser-
77) were shown previously to contribute to
both PI(4,5)P2 and RNA binding site 33, 45.
Thus, as anticipated, the TD1 binding site
overlaps the MA binding site for RNA and
PI(4,5)P2 (Figure 6). These observations are
discussed in more detail below.
Effects of inhibitors on virus infectivity
and cell toxicity
To test the effects of DDD and
TD1-3 on HIV-1 replication, TZM-bl assays
were employed 60, 61. In this case, HIV-1
infected CEM-SS T cells were treated with
increasing concentrations of compounds and
incubated in the presence of TZM-bl
indicator cells, which express E. coli β-
galactosidase (β-gal) when infected with
HIV-1 60, 61. Due to the protocol employed
(see Experimental Procedures), compound
inhibition of any virus replication step may
be detected. As shown in Figure 7, DDD and
TD1-3 concentrations of 1-5 µM were
sufficient to yield a 50% reduction (EC50) of
HIV-1 replication in this system.
Unfortunately, when tested for cellular
cytotoxicity using an MTS assay (62;
Materials and Methods), DDD gave a 50%
cytotoxic concentration (CC50) of about 5
µM, while TD1-3 CC50 values ranged from
10-20 µM (Figure 6). These results imply
that the DDD and TD scaffolds may be too
toxic for anti HIV-1 drug development, but
overall, our results suggest that it should be
possible to target the MA PI(4,5)P2-RNA
binding pocket as a novel antiviral approach.
DISCUSSION
The matrix domain of the HIV-1 PrGag
protein directs PrGag proteins to assembly
sites at the PM, and facilitates the
incorporation of full length HIV-1 envelope
proteins into virions 10-25. MA also has been
shown to bind nucleic acids 29-35. Recent
experiments demonstrated that the ability of
MA to bind RNA increases the selectivity of
MA for PI(4,5)P2-rich membrane assembly
sites 32-34,55 . Based on these observations,
we  and others have proposed a chaperone
model in which MA-RNA binding protected
PrGag proteins from association with
inappropriate intracellular membranes prior
to delivery to the PI(4,5)P2-rich PM 32-34,55.
Consistent with this model, our recent
results indicate that the MA RNA and
PI(4,5)P2 binding sites overlap 33.
Based on the above observations, we
reasoned that it might be possible to identify
compounds that bind and possibly inhibit
HIV-1 MA by virtue of their abilities to
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interfere with MA binding to RNA. To this
end, we developed a competitor screen in
which compounds that inhibit MA-RNA
binding were identified. Using this assay, we
identified five compounds that consistently
inhibited binding, four of which were
available in higher quantities. As shown in
Figure 1, one of these, DDD, is a
naphthalene derivative. The other three
(TD1-3) share the same thiadiazolane
backbone that is closely related to the
glitazone scaffold present on several drugs
that have been used to treat type 2 diabetes
(Figure 1; 57, 58). Since two glitazones,
pioglitazone and rosiglitazone, were
available (Figure 1), we tested their abilities
to inhibit MA-RNA binding, but found them
inactive (Table 1). At this point, we do not
know whether this inactivity is due to the
glitazone scaffold itself, or to the specific R
groups on pioglitazone and rosiglitazone.
To assess the specificities of the four
compounds chosen from primary and secondary
screens, we performed additional assays. EMSA
assays demonstrated that DDD mildly inhibited MA-
RNA binding, while TD1-3 significantly inhibited
binding (Figure 2). These results complemented our
initial observations and confirmed that
thiadiazolanes do not simply block binding in a non-
specific fashion.  FA competition binding results
(Figure 3) provided an independent confirmation of
plate binding and EMSA assays, and yielded TD1-3
Ki inhibition constants in the 5-10 µM range (Figure
3).  Bead binding assays additionally showed that
thiodiazolanes reduced MA binding to an HIV-1
RNA fragment and PI(4,5)P2-containing liposomes
(Figure 4). To determine which MA residues might
be involved in thiadiazolane binding, NMR chemical
shift perturbation experiments with TD1were
conducted. These investigations revealed that
residues in the C-terminal portion of helix II (Glu-
40, Leu-41, Arg-43), and several residues in the MA
β-II-V cleft (Trp-16, Leu-21, Val-46, Lys-73, Leu-
75 and Ser-77) were affected by titrations with a
TD-1 compound (Figures 5-6). Interestingly, these
β-II-V cleft residues previously were shown to
contribute to both PI(4,5)P2 and RNA binding 33, 45.
These data suggest that TD compounds act as
competitive inhibitors of MA-RNA and MA-
PI(4,5)P2 interactions. It will be of interest to
determine the structure of thiadiazolane-bound MA,
both to verify this mechanism of action, and to help
in the design of higher affinity MA ligands.
Despite their promising in vitro
activities, TD1-3 showed somewhat
disappointing in vivo inhibitory activities.
Although they demonstrated EC50
concentrations of 1-5 µM (Figure 7), their
cytotoxicities were such that therapeutic
windows were only 3-5. At this point, we do
not know whether the observed TD1-3
cytotoxicities stem from the thiadiazolane
structure or are specific to these three
thiadiazolanes. Nevertheless, our results
clearly demonstrate the possibility of
targeting the MA-PI(4,5)P2-RNA binding
pocket as a novel antiviral approach.
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TABLE AND FIGURE LEGENDS
Table 1. Plate binding assay values for MyrMA-RNA binding inhibitors and analogues. Plate
binding assays of MyrMA-Sel15 RNA binding inhibition were performed with 10 µM concentrations of
inhibitor candidates as described in the Experimental Procedures section. Values listed correspond to
MyrMA-RNA binding signals normalized to DMSO controls such that a value of 1.0 is equivalent to the
DMSO control and indicates no inhibition, whereas lower values are indicative of binding inhibition.
Available compounds with normalized primary screen values of <0.6 were rescreened in triplicate in
secondary assays Due to unavailability or lack of inhibitory activity, secondary screening of the
compounds TD4, TD5, pioglitazone, and rosiglitazone was not done (ND).
Table 2. MA residues showing significant chemical shifts on TD1 binding.1H -15N NMR chemical
shifts observed for MA bound to TD1 at pH 5.5 and 35°C are tabulated. The association of TD1 and MA
was monitored by observing changes in the 1H–15N cross-peaks in the HSQC spectra of 15N labeled MA
upon titration with TD1. Shown are residues that exhibited significant chemical shifts ( ≥ 0.10 ppm) upon
titrations with TD1. The extent of the combined 1H  and 15N (ΔδHN)  chemical-shift changes was
calculated according to the formula  ΔδHN = ((Δδ 1H)2 + (Δδ 15N)2 )_. Indicated are the final ΔδHN
titrations of TD1 with TD1: MA ratio of 16:1.
Figure 1. Chemical structures of MyrMA-RNA binding inhibitors and analogues. The compounds
TD1 (2-(2-chloro-6-methylphenyl)-4-(cyclopropylmethyl)-1,2,4-thiadiazolane-3,5-dione; 296.8 Da), TD2
(4-methyl-2-(1-naphthyl)-1,2,4-thiadiazolane-3,5-dione; 258.3 Da), TD3 (4-(cyclopropylmethyl)-2-(3,5-
dimethylisoxazol-4-yl)-1,2,4-thiadiazolane-3,5-dione ; 267.3 Da), and DDD (2,3-dichloro-1,4-
dihydronaphthalene-1,4-dione; 227 Da) were observed in screens to inhibit MyrMA-RNA binding. Also
shown are the general structures of thiadiazolane-3,5-diones and related glitazones.  Note that other
thiadiazolane-3,5-diones screened were TD4 (2-(2-chloro-6-methylphenyl)-4-( cyclopropylmethyl)-
1,2,4-thiadiazolane-3,5-dione) and TD5 (2-(3,5-dimethylisoxazol-4-yl)-4-(4-fluorophenyl)- 1,2,4-
thiadiazolane-3,5-dione) ; and that the glitazones pioglitazone (5-((4(2-(5-ethylpyridin-2-
yl)ethoxy)phenylmethyl)-1,3- thiadiazolane-2,4-dione) and rosiglitazone ((RS)-5-4-2-(methyl(pyridin-2-
yl)amino)ethoxybenzyl) thiadiazolane-2,4-dione) also were assayed.
Figure 2. Electrophoretic mobility shift assays. Electrophoretic mobility shift assays (EMSA) were
performed with 15 µM Sel25 or Sel15 RNAs and 15 µM concentrations of HIV-1 MyrMA (MA) or NC
proteins as indicated. In each panel, the far right lane represents an RNA only incubation and the leftmost
five lanes represent assays performed in the presence of 1 ml (5%) DMSO or 50 µM final concentrations
of the indicated compounds in DMSO. Bound (B) and free (F) RNAs were detected after electrophoresis
by staining. Note that TD1-3 impaired RNA binding to MyrMA but not to NC.
Figure 3. Fluorescence anisotropy competition binding assays. FA competition binding assays were
performed with 5 nM FITC-Sel15 in the absence (panel A) or presence (panel B) of 1 µM MyrMA and
increasing concentrations of compounds or DMSO (as a control) that were titrated to achieve final
compound concentrations of 0-60 µM. Competition assays were plotted as millipolarization versus
inhibitor concentration and fitted assuming exponential decay binding curves. Note that DMSO and all
compounds in DMSO reduced FA signals of free FITC-Sel15, presumably due to probe quenching (panel
A). However, in the presence of MyrMA (panel B), the compounds TD1-3 showed greater effects on FA
signals than DMSO or DDD, consistent with reductions in MyrMA-RNA binding levels.
Figure 4. Fluorescent bead binding assays. MyrMA beads were incubated either with DMSO (control)
or with 50 µM concentrations of the indicated compounds, and then supplemented with either 0.5 µM
16
FITC-Sel25 RNA (A), fluorescently labeled HIV-1 viral RNA (nt 1-4001; 23 µM total nucleotide
concentration) (B), or 4 µg NBD-DOPE-tagged PI(4,5)P2-containing liposomes (C). Following binding
incubations, beads were pelleted, washed, resuspended in wash buffer, and imaged by fluorescence
microscopy under identical gain and exposure settings. For quantitation, background-subtracted bead
brightness values were calculated, averaged from multiple (n>8) beads for each incubation, and
normalized to DMSO control samples. Fluorescent ligand binding values are plotted relative to DMSO
controls in each panel.
Figure 5. NMR of MA-TD1 binding. (A) Shown is an overlay of 2D 1H-15N  HSQC spectra of  15N-
labeled MA obtained at pH 5.5 and 35°C upon titration with TD1 at the following TD1: MA ratios: 0:1
(black), 1:1 (blue), 4:1(green), 8:1 (yellow), and 16:1 (red). Indicated in circles are some of the shifted
residues. B-E show representative expanded portions of the 2D 1H-15N HSQC overlay, with the same
titrations ratios as in (A). F-I show binding curves of 1H-15N NMR chemical shift titration data from
panels B-E. Note that residue A100 is provided as an example of a residue that is not affected by drug
binding, whereas L21, K32, and S77 are examples of residues that were affected by binding.
Figure 6. MA binding sites of TD1, RNA and PI(4,5)P2. Shown are surface representations of MA (pdb
ID: 1UPH). Residues that exhibited significant chemical shift changes (ΔδHN ≥ 0.10 ppm) on TD1
binding are colored in blue (A); Sel15 RNA binding residues are highlighted in red (B); and di-C4-
PI(4,5)P2 binding residues are highlighted in green (C). For convenience a subset of the binding residues
is labeled.
Figure 7. Cell culture toxicity and virus replication assays. Cell culture toxicity (circles) and anti-HIV-
1 inhibition assays (boxes) were performed as described in the Materials and Methods with various
concentrations of the indicated compounds. Results are plotted as graphs of percentage of cell viability or
virus replication relative to mock (DMSO) controls, versus compound concentrations.
Compound 1° screen 2° screen
DDD 0.58 0.48 +/- 0.17
TD1 0.09 0.19 +/- 0.03
TD2 0.08 0.12 +/- 0.06
TD3 0.11 0.34 +/- 0.09
TD4 0.47 ND
TD5 0.70 ND
pioglitazone 0.93 ND
rosiglitazone 0.95 ND
Table 1. Plate binding assay values for MyrMA-RNA binding inhibitors and analogues. Plate
binding assays of MyrMA-Sel15 RNA binding inhibition were performed with 10 µM concentrations of
inhibitor candidates as described in the Experimental Procedures section. Values listed correspond to
MyrMA-RNA binding signals normalized to DMSO controls such that a value of 1.0 is equivalent to the
DMSO control and indicates no inhibition, whereas lower values are indicative of binding inhibition.
Available compounds with normalized primary screen values of <0.6 were rescreened in triplicate in
secondary assays Due to unavailability or lack of inhibitory activity, secondary screening of the
compounds TD4, TD5, pioglitazone, and rosiglitazone was not done (ND).
Residue Δδ1H-15N (≥ 0.10 ppm)
6 Ser 0.11
16 Trp 0.17
21 Leu 0.11
32 Lys 0.12
35 Val 0.12
40 Glu 0.11
41 Leu 0.16
43 Arg 0.10
46 Val 0.10
47 Asn 0.15
60 Ile 0.11
73 Glu 0.16
75 Leu 0.21
77 Ser 0.12
78 Leu 0.10
 Table 2. MA residues showing significant chemical shifts on TD1 binding.11H -15N NMR chemical
shifts observed for MA bound to TD1 at pH 5.5 and 35°C are tabulated. The association of TD1 and MA
was monitored by observing changes in the 1H–15N cross-peaks in the HSQC spectra of 15N labeled MA
upon titration with TD1. Shown are residues that exhibited significant chemical shifts ( ≥ 0.10 ppm) upon
titrations with TD1. The extent of the combined 1H  and 15N (ΔδHN)  chemical-shift changes was
calculated according to the formula  ΔδHN = ((Δδ 1H)2 + (Δδ 15N)2 )-1/2. Indicated are the final ΔδHN
titrations of TD1 with TD1: MA ratio of 16:1.
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